World1 month ago
Apalutamide Demonstrates Real-World OS Benefit vs Enzalutamide in mCSPC
Data from a real-world study showed that treatment with apalutamide (Erleada) led to a statistically significant improvement in overall survival (OS) at 24 months compared with...
